{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:29Z","timestamp":1786115069925,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.trecan.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:12:22Z","timestamp":1774959142000},"page":"634-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mesothelioma: a systemic therapy clinical trials snapshot"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0762-1726","authenticated-orcid":false,"given":"Maurice","family":"Dungey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushad","family":"Malhotra Mukhtyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Dulloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.03.003_bb0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-025-00640-3","article-title":"Pleural mesothelioma","volume":"11","author":"Fennell","year":"2025","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.trecan.2026.03.003_bb0010","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jtho.2025.06.020","article-title":"Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations","volume":"20","author":"Carbone","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0025","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of pleural mesothelioma: ASCO guideline update","volume":"43","author":"Kindler","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.6004\/jnccn.2024.0014","article-title":"NCCN guidelines\u00ae insights: mesothelioma: pleural, version 1.2024","volume":"22","author":"Stevenson","year":"2024","journal-title":"J. Natl. Compr Canc. Netw."},{"key":"10.1016\/j.trecan.2026.03.003_bb0035","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0040","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.03.003_bb0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.trecan.2026.03.003_bb0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.03.003_bb0055","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.03.003_bb0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-meso randomized clinical trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0065","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101432","article-title":"Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial","volume":"48","author":"Fennell","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.trecan.2026.03.003_bb0075","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0080","doi-asserted-by":"crossref","first-page":"S1423","DOI":"10.1016\/j.annonc.2022.08.058","article-title":"LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin\/pemetrexed (CP) in treatment-naive (1L) non-small cell lung cancer (NSCLC): a phase Ib\/II trial","volume":"33","author":"Ahn","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0085","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.03.003_bb0090","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cllc.2025.04.008","article-title":"Breaking through: immunotherapy innovations in pleural mesothelioma","volume":"26","author":"Sofianidi","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.trecan.2026.03.003_bb0095","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1038\/s41467-025-61691-4","article-title":"Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial","volume":"16","author":"Fennell","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.003_bb0100","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1038\/s41591-025-03958-3","article-title":"Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses","volume":"12","author":"Reuss","year":"2025","journal-title":"Nat. Med"},{"key":"10.1016\/j.trecan.2026.03.003_bb0105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10555-006-9006-2","article-title":"Transforming growth factor-beta in cancer and metastasis","volume":"25","author":"Jakowlew","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.trecan.2026.03.003_bb0110","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","article-title":"Clinical development of therapies targeting TGF\u03b2: current knowledge and future perspectives","volume":"31","author":"Ciardiello","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0115","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","article-title":"TIGIT, a novel immune checkpoint therapy for melanoma","volume":"14","author":"Tang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2026.03.003_bb0120","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.003_bb0125","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184043","article-title":"Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response","volume":"135","author":"Tao","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.03.003_bb0130","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201811","article-title":"LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy","volume":"218","author":"Sharma","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.03.003_bb0135","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1200\/JCO.2024.42.16_suppl.2526","article-title":"Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors","volume":"42","author":"Roda","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0140","doi-asserted-by":"crossref","first-page":"CT259","DOI":"10.1158\/1538-7445.AM2024-CT259","article-title":"Abstract CT259: results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1\/2 trial show evidence of single-agent activity in advanced solid tumors","volume":"84","author":"Atkinson","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.003_bb0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.trecan.2026.03.003_bb0150","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1038\/s41467-024-49842-5","article-title":"A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.003_bb0155","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.03.003_bb0160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2020.00126","article-title":"Antiangiogeneic strategies in mesothelioma","volume":"10","author":"Nowak","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0165","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2026.03.003_bb0175","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0185","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2025.43.16_suppl.8511","article-title":"First report of efficacy and safety results from a phase 2 trial evaluating BNT327\/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma","volume":"43","author":"Cheng","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0190","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0195","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jtho.2024.09.088","article-title":"OA18.04 pembrolizumab plus lenvatinib in second-line pleural mesothelioma patients: a single arm phase II study (PEMMELA cohort 2)","volume":"19","author":"Douma","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0200","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0205","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0210","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4149\/neo_2014_031","article-title":"Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study","volume":"61","author":"Capkova","year":"2014","journal-title":"Neoplasma"},{"key":"10.1016\/j.trecan.2026.03.003_bb0215","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.03.003_bb0220","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1038\/s41598-021-86834-7","article-title":"Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression","volume":"11","author":"Busacca","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.03.003_bb0225","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2026.03.003_bb0230","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s43018-022-00419-5","article-title":"Accelerating innovations in systemic therapy for pleural mesothelioma","volume":"3","author":"Fennell","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.03.003_bb0235","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.003_bb0240","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41467-024-46495-2","article-title":"PRMT5 is an actionable therapeutic target in CDK4\/6 inhibitor-resistant ER+\/RB-deficient breast cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.003_bb0245","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.03.003_bb0250","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.03.003_bb0255","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.ejca.2024.114981","article-title":"Results from CA240-0007, a phase 1\/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)","volume":"211","author":"Rodon","year":"2024","journal-title":"Euro. J. Cancer"},{"key":"10.1016\/j.trecan.2026.03.003_bb0260","doi-asserted-by":"crossref","first-page":"B011","DOI":"10.1158\/2326-6074.TUMIMM24-B011","article-title":"Abstract B011: MTA-cooperative PRMT5 inhibition (BMS-986504) induces MTAP del tumor cell-intrinsic immune evasion and regulation","volume":"12","author":"Hai","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.03.003_bb0265","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0270","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","article-title":"MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial","volume":"16","author":"Gounder","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.03.003_bb0275","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108946","article-title":"Pharmacological CDK4\/6 inhibition reveals a p53-dependent senescent state with restricted toxicity","volume":"41","author":"Wang","year":"2022","journal-title":"Embo J."},{"key":"10.1016\/j.trecan.2026.03.003_bb0280","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1038\/sj.onc.1201870","article-title":"Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression","volume":"16","author":"Frizelle","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2026.03.003_bb0285","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0290","doi-asserted-by":"crossref","first-page":"12405","DOI":"10.1073\/pnas.0605579103","article-title":"Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon","volume":"103","author":"Overholtzer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.trecan.2026.03.003_bb0295","doi-asserted-by":"crossref","first-page":"E2441","DOI":"10.1073\/pnas.1212021109","article-title":"The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain","volume":"109","author":"Lamar","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.trecan.2026.03.003_bb0300","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1101\/gad.1664408","article-title":"TEAD mediates YAP-dependent gene induction and growth control","volume":"22","author":"Zhao","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.trecan.2026.03.003_bb0305","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1038\/s41591-025-04029-3","article-title":"YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial","volume":"31","author":"Yap","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.03.003_bb0310","doi-asserted-by":"crossref","first-page":"S600","DOI":"10.1016\/j.annonc.2025.08.1488","article-title":"919O A first-in-human study of oral IAG933 in adult patients with advanced mesothelioma and other solid tumours","volume":"36","author":"Garralda","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0315","doi-asserted-by":"crossref","first-page":"CT153","DOI":"10.1158\/1538-7445.AM2025-CT153","article-title":"Abstract CT153: first in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumors","volume":"85","author":"Falchook","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.003_bb0320","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s44321-025-00278-4","article-title":"De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma","volume":"17","author":"Xu","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.trecan.2026.03.003_bb0325","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","article-title":"Brigatinib in NF2-related schwannomatosis with progressive tumors","volume":"390","author":"Plotkin","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.03.003_bb0330","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.03.003_bb0335","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0340","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1200\/JCO.2023.41.16_suppl.3094","article-title":"EZH2\/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: preliminary phase II results","volume":"41","author":"Drescher","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0345","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1158\/1538-7445.AM2022-3939","article-title":"Abstract 3939: preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918\/EEDi-5273 for cancer therapy","volume":"82","author":"Zhu","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.003_bb0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/PO.20.00260","article-title":"Durable response to vismodegib in PTCH1 F1147fs mutant relapsed malignant pleural mesothelioma: implications for mesothelioma drug treatment","volume":"5","author":"Popat","year":"2021","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00048","article-title":"STRN-ALK rearranged malignant peritoneal mesothelioma with dramatic response following ceritinib treatment","volume":"3","author":"R\u00fcschoff","year":"2019","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0360","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0365","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1067\/mtc.2001.111176","article-title":"The alpha folate receptor is highly activated in malignant pleural mesothelioma","volume":"121","author":"Bueno","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.trecan.2026.03.003_bb0370","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10637-019-00768-6","article-title":"A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","volume":"37","author":"Sharman","year":"2019","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.trecan.2026.03.003_bb0375","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40265-024-02066-9","article-title":"Targeting DNA damage response deficiency in thoracic cancers","volume":"84","author":"Bzura","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.trecan.2026.03.003_bb0380","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.trecan.2026.03.003_bb0385","article-title":"Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.trecan.2026.03.003_bb0390","doi-asserted-by":"crossref","first-page":"CT263","DOI":"10.1158\/1538-7445.AM2025-CT263","article-title":"Abstract CT263: efficacy and multiomic analysis of Niraparib in relapsed mesothelioma: NERO a randomized phase II trial","volume":"85","author":"Fennell","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.03.003_bb0395","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8017","article-title":"Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial","volume":"42","author":"Fennell","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.03.003_bb0400","doi-asserted-by":"crossref","first-page":"CT240","DOI":"10.1158\/1538-7445.AM2023-CT240","article-title":"Abstract CT240: on-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies","volume":"83","author":"Tkaczuk","year":"2023","journal-title":"Cancer Res."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:10:09Z","timestamp":1785975009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2405803326000580"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.03.003","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelioma: a systemic therapy clinical trials snapshot","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}